• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinipace Acquires Worldwide Clinical Research, Changes Name

Clinipace Acquires Worldwide Clinical Research, Changes Name

November 23, 2009
CenterWatch Staff

Morrisville, N.C.-based Clinipace, a technology- focused contract research organization (CRO), acquired Worldwide Clinical Research, a Midwest-based CRO as part of its global expansion.  With the acquisition, Clinipace has changed its name to Clinipace Worldwide. 

Worldwide Clinical Research adds operations in South America, an emerging market. The company provides core traditional clinical operations, including monitoring, site management and project management.  These services will now be augmented by Clinipace’s focus on technology-driven clinical research solutions to provide clients with full-service, global research services. Worldwide Clinical Research has more  than 30 employees, including six monitors. The acquisition doubles the number of Clinipace employees to 60. 

“Having honed our expertise on electronic data management services, we felt it was critical to expand both our clinical operations expertise and global presence in order to support our growth,” said Jeff Williams, Clinipace’s CEO. 

The companies combined have managed more than 70 contract research projects conducted globally at almost 3,000 sites with 100,000 patients. 

“We think it is great growth time for a CRO with our strategy,” Williams said. “Lots of smaller CROs, the more traditional ones, may find it to be more difficult now. But in our case, the essence of our strategy is to leverage technology in order to improve the efficiencies of the trial. That translates into better visibility for the sponsors in terms of what is happening in the trial. But it also translates into lower costs.” 

That is the value proposition Clinipace provides for its target market of small and mid-sized biotech, pharmaceutical and medical device companies. “There’s pent up demand that is going to loosen up in 2010,” Williams said. The company’s headquarters will remain in Research Triangle Park, N.C., with additional domestic operations in Overland Park, Kan., and South American operations based in São Paulo, Brazil; Buenos Aires, Argentina; and Lima, Peru. 

Clinipace, founded in 2003, said it has experienced triple-digit growth in the past 12 months and is expected to continue to hire in all locations throughout 2010 to support its growing CRO business. Williams said by the end of 2010, the company could have 100 employees. 

“We’ll continue to look for acquisitions. [Worldwide Clinical Research] had a primary focus on oncology though they have done lots of other things. Our strength has been cardiovascular, CNS and medical devices. We will look for other opportunities where we can flush out therapeutic depth. At the same time, to grow a CRO you need to have a global presence. The first step for us was the South American operations,” Williams said. 

Barbara Geiger, president and CEO of Worldwide Clinical Research, will transition to executive vice president of clinical operations and will be responsible for directing all clinical operations for Clinipace Worldwide, from its Kansas office.  Geiger brings more than 25 years of experience in the conduct and management of phase I through IV clinical trials.  Prior to founding Worldwide Clinical Research in 2000, she spent 10 years at global CROs. 

“By combining forces, we can better serve our clients with a fully integrated end-to-end development solution and expert services,” said Geiger.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing